Potentiality and Boundaries of Use of Sorafenib in Patients with Hepatocellular Carcinoma: Awaiting the Results of Ongoing Clinical Trials

Potentiality and Boundaries of Use of Sorafenib in Patients with Hepatocellular Carcinoma: Awaiting the Results of Ongoing Clinical Trials

No systemic therapy had been proven effective in patients with advanced hepatocellular carcinoma (HCC) until 2007, when a large randomized trial with sorafenib demonstrated a clinically relevant prolongation of survival. Currently, sorafenib represents standard treatment for patients with advanced H...

Full description

Bibliographic Details
Main Authors: Di Maio, Massimo, Daniele, Gennaro, Piccirillo, Maria Carmela, Giordano, Pasqualina, Signoriello, Giuseppe, Daniele, Bruno, Perrone, Francesco
Format: Online
Language:English
Published: MDPI 2012
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712698/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712698/

Similar Items